Pharmaceutical School of Jinan University, Guangzhou, China School of Pharmacy, Wenzhou Medical College, Wenzhou, China.
Eur J Clin Invest. 2011 Aug;41(8):836-45. doi: 10.1111/j.1365-2362.2011.02473.x. Epub 2011 Feb 8.
C-X-C chemokine ligand 16 (CXCL16) is a scavenger receptor for oxidized low-density lipoprotein that has been shown to promote atherogenic effects in vivo and to predict the long-term mortality in acute coronary syndrome. We conducted a cross-sectional study to test the hypothesis that elevated CXCL16 concentrations are associated with the change in renal function in patients with chronic kidney disease (CKD) at different stages of disease.
Two hundred and forty subjects including 200 patients with CKD (146 CKD from outpatients and 54 CKD with long-term haemodialysis) and 40 normal control subjects were recruited into this study. All CKD subjects underwent echocardiograms to assess left ventricular mass index. Plasma levels of CXCL16 and other relevant clinical and biochemical parameters in all subjects were obtained upon standard clinical examinations.
Plasma CXCL16 levels were significantly increased with the development of CKD from early- and end-stage (P < 0·001 for trend) and significantly higher in CKD subjects than those of normal subjects (P<0·001). Furthermore, plasma CXCL16 levels in CKD patients with type 2 diabetes mellitus (DM) were higher than those of CKD patients without DM. Multiple stepwise regression analyses indicated that plasma CXCL16 levels were independently associated with estimated glomerular filtration rate, C-reactive protein and adiponectin (all P<0·05).
Plasma CXCL16 levels are significantly increased with the development of early- to end-stage CKD and are independently associated with the change in renal function. Elucidating the role of CXCL16 as a biomarker or disease modifier in CKD progression requires further study.
C-X-C 趋化因子配体 16（CXCL16）是氧化型低密度脂蛋白的清道夫受体，已被证明在体内具有促进动脉粥样硬化作用，并可预测急性冠状动脉综合征的长期死亡率。我们进行了一项横断面研究，以检验以下假设：在不同疾病阶段的慢性肾脏病（CKD）患者中，升高的 CXCL16 浓度与肾功能变化相关。
本研究共纳入 240 名受试者，包括 200 名 CKD 患者（146 名门诊 CKD 患者和 54 名长期血液透析的 CKD 患者）和 40 名正常对照者。所有 CKD 患者均接受超声心动图检查以评估左心室质量指数。所有受试者均进行标准临床检查以获得 CXCL16 及其他相关临床和生化参数的血浆水平。
随着 CKD 从早期和终末期的发展，血浆 CXCL16 水平显著升高（趋势 P<0·001），并且 CKD 患者的血浆 CXCL16 水平显著高于正常对照组（P<0·001）。此外，患有 2 型糖尿病（DM）的 CKD 患者的血浆 CXCL16 水平高于无 DM 的 CKD 患者。多元逐步回归分析表明，血浆 CXCL16 水平与估计肾小球滤过率、C 反应蛋白和脂联素独立相关（均 P<0·05）。
随着早期到终末期 CKD 的发展，血浆 CXCL16 水平显著升高，并且与肾功能变化独立相关。阐明 CXCL16 作为 CKD 进展的生物标志物或疾病修饰因子的作用需要进一步研究。
